9 Amendments of Marije CORNELISSEN related to 2012/2155(BUD)
Amendment 2 #
Motion for a resolution
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Welcomes this call for the EGF financial contribution by the Swedish Government even though this Member State is opposed to the EGF after 2013;
Amendment 3 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Notes that the Swedish authorities submitted the application for EGF financial contribution on 23 December 2011, supplemented by additional information up to 16 April 2012, and that its assessment was made available by the European Commission on 16 July 2012; welcomes the fact that therelatively speedy evaluation process and submission of additional information by Sweden were speedy and accurate;
Amendment 4 #
Motion for a resolution
Paragraph 4 a (new)
Paragraph 4 a (new)
4a. Regrets the decision of AstraZeneca to increase R&D investments in countries like China or Russia, reflecting a strategy that is detrimental to highly skilled jobs in the Union and contrary to Europe 2020 strategy;
Amendment 5 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Welcomes the fact that, in order to provide workers with speedy assistance, the Swedish authorities decided to start the implementation of the measures on 26 October 2011 well ahead of the final decision on granting the EGF support for the proposed coordinated package;
Amendment 6 #
Motion for a resolution
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Calls for trade reciprocity in trade between the Union and third countries as an essential condition for EU companies to gain access to new non-European markets;
Amendment 7 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Notes that the workers dismissed from Astra Zeneca are highly skilled and educated and therefore require specific approach; regrets that the Swedish authorities do not inform about the areas in which the training measures and occupational guidance have been planned and if and how these have been adapted to the local labour markets affected by the dismissal;
Amendment 8 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Notes that the R&D activities carried out in Lund site have been transferred by AstraZeneca to Mölndal site; inquires if any of the Lund workers were offered the possibility to be employed in the enlarged site of Mölndal instead of being dismissed;
Amendment 10 #
Motion for a resolution
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Notes that the coordinated package foresees several participation incentives to encourage participation in the measures: job search allowance of EUR 7 170 (calculated for an average of 6 months of participation) mobility allowance of EUR 500; recalls that the EGF support should be primarily allocated to training and job search as well as training programs instead of contributing directly to unemployment benefits which are the responsibility of national institutions;
Amendment 11 #
Motion for a resolution
Paragraph 10 a (new)
Paragraph 10 a (new)
10a. Welcomes the fact that Swedish authorities plan to organise an awareness raising campaign about activities supported by the EGF;